BOSTON (Reuters) - In a study that could change the way hip fractures are treated, doctors have discovered that giving the Novartis osteoporosis drug Reclast can prevent later fractures and helps ...

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

For the first time, an osteoporosis drug has reduced deaths and prevented new fractures in elderly patients with broken hips, according to new research. Some experts called the drop in deaths ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

WASHINGTON (Reuters) - Swiss drugmaker Novartis A said Friday it had won U.S. approval to sell the first once-a-year treatment for the bone-thinning disease osteoporosis. Sign up here. The drug, ...

U.S. FDA Approves Novartis Corporation's Reclast, the First and Only Single-Dose Treatment Regimen for Paget's Disease of the Bone NEW YORK, April 17 -- The U.S. Food and Drug Administration (FDA) has ...